{
  "detailed_scores": {
    "team": {
      "score": 0,
      "justification": "",
      "reasoning": ""
    },
    "technology": {
      "score": 0,
      "justification": "",
      "reasoning": ""
    },
    "market": {
      "score": 0,
      "justification": "",
      "reasoning": ""
    },
    "gtm_traction": {
      "score": 0,
      "justification": "",
      "reasoning": ""
    },
    "competitive": {
      "score": 0,
      "justification": "",
      "reasoning": ""
    }
  },
  "overall_score": {
    "overall": 5.0,
    "team": 5,
    "technology": 5,
    "market": 5,
    "gtm_traction": 5,
    "competitive_positioning": 5,
    "scale": "1-10 (10 = highest)",
    "weighting": "Tech 30%, Team 25%, Market 25%, GTM 10%, Competitive 10%"
  },
  "swot_analysis": {
    "strengths": "Strong founding team with relevant experience and innovative, patented technology.",
    "weaknesses": "Lack of information about the market opportunity, go-to-market strategy, and competitive landscape.",
    "opportunities": "The company could potentially address a significant problem in the field of rare genetic diseases.",
    "threats": "The lack of information about the competitive landscape makes it difficult to assess potential threats."
  },
  "strategic_recommendations": [
    "Provide more information about the market size and target customers.",
    "Develop a clear go-to-market strategy and provide metrics related to customer acquisition and retention.",
    "Provide more information about the competitive landscape and the company's unique selling proposition."
  ],
  "executive_summary": "Comprehensive VC analysis across 5 categories with weighted scoring.",
  "strengths": [],
  "weaknesses": [
    "Lack of information about the market opportunity, go-to-market strategy, and competitive landscape."
  ],
  "company_overview": {
    "name": "Protirna Therapeutics, Inc. - mRNA therapeutics company founded by Dr. Sarah Chen (PhD Stanford, former Moderna scientist) and Dr. Michael Rodriguez (MD/PhD Harvard, 10 years pharma experience at Pfizer). Targeting rare genetic diseases with proprietary delivery platform.",
    "description": "",
    "mission": "",
    "therapeutic_focus": "Protirna Therapeutics, Inc. - mRNA therapeutics company founded by Dr. Sarah Chen (PhD Stanford, former Moderna scientist) and Dr. Michael Rodriguez (MD/PhD Harvard, 10 years pharma experience at Pfizer). Targeting rare genetic diseases with proprietary delivery platform. Problem: Current gene therapies have poor delivery efficiency (only 5-10% reach target cells). Our proprietary lipid nanoparticle platform achieves 85% delivery efficiency in preclinical studies. Platform validated in 3 disease",
    "business_model": "",
    "stage": "Unknown"
  },
  "technology_profile": {
    "drug_modality": "mrna, gene therapy,",
    "mechanism_of_action": "Protirna Therapeutics, Inc. - mRNA therapeutics company founded by Dr. Sarah Chen (PhD Stanford, former Moderna scientist) and Dr. Michael Rodriguez (MD/PhD Harvard, 10 years pharma experience at Pfizer). Targeting rare genetic diseases with proprietary delivery platform. Problem: Current gene therapies have poor delivery efficiency (only 5-10% reach target cells). Our proprietary lipid nanoparticle platform achieves 85% delivery efficiency in preclinical studies. Platform validated in 3 disease",
    "platform_technology": "Protirna Therapeutics, Inc. - mRNA therapeutics company founded by Dr. Sarah Chen (PhD Stanford, former Moderna scientist) and Dr. Michael Rodriguez (MD/PhD Harvard, 10 years pharma experience at Pfizer). Targeting rare genetic diseases with proprietary delivery platform. Problem: Current gene therapies have poor delivery efficiency (only 5-10% reach target cells). Our proprietary lipid nanoparticle platform achieves 85% delivery efficiency in preclinical studies. Platform validated in 3 disease",
    "pipeline": [],
    "differentiation": "",
    "ip_status": "Problem: Current gene therapies have poor delivery efficiency (only 5-10% reach target cells). Our proprietary lipid nanoparticle platform achieves 85% delivery efficiency in preclinical studies. Platform validated in 3 disease models. Filed 4 patents, 2 granted. Traction: Completed successful IND-enabling studies. Partnership discussions with Roche and Novartis. Received $2.5M NIH SBIR grant. 3 patients enrolled in compassionate use program showing 40% improvement in muscle function. Funding: R"
  },
  "market_analysis": {
    "target_market": "",
    "market_size": "Market: Rare disease gene therapy market is $8.2B globally, growing 15% annually. TAM $45B by 2030. Target initial indication: Duchenne Muscular Dystrophy (DMD) - 300,000 patients globally, current treatments only $2-5B market but poor efficacy.",
    "competitive_landscape": "",
    "key_competitors": [],
    "market_opportunity": "",
    "regulatory_pathway": "Problem: Current gene therapies have poor delivery efficiency (only 5-10% reach target cells). Our proprietary lipid nanoparticle platform achieves 85% delivery efficiency in preclinical studies. Platform validated in 3 disease models. Filed 4 patents, 2 granted. Funding: Raising $15M Series A. Use of funds: 60% clinical trial execution, 25% manufacturing scale-up, 15% team expansion. Timeline: IND filing Q2 2025, Phase 1 start Q4 2025. Team of 12 including 3 PhDs and regulatory consultant."
  },
  "team_profile": {
    "leadership_team": [],
    "advisory_board": [],
    "key_expertise": "",
    "academic_affiliations": "Protirna Therapeutics, Inc. - mRNA therapeutics company founded by Dr. Sarah Chen (PhD Stanford, former Moderna scientist) and Dr. Michael Rodriguez (MD/PhD Harvard, 10 years pharma experience at Pfizer). Targeting rare genetic diseases with proprietary delivery platform. Funding: Raising $15M Series A. Use of funds: 60% clinical trial execution, 25% manufacturing scale-up, 15% team expansion. Timeline: IND filing Q2 2025, Phase 1 start Q4 2025. Team of 12 including 3 PhDs and regulatory consult",
    "industry_experience": "Protirna Therapeutics, Inc. - mRNA therapeutics company founded by Dr. Sarah Chen (PhD Stanford, former Moderna scientist) and Dr. Michael Rodriguez (MD/PhD Harvard, 10 years pharma experience at Pfizer). Targeting rare genetic diseases with proprietary delivery platform."
  },
  "funding_profile": {
    "funding_stage": "",
    "amount_raising": "Funding: Raising $15M Series A. Use of funds: 60% clinical trial execution, 25% manufacturing scale-up, 15% team expansion. Timeline: IND filing Q2 2025, Phase 1 start Q4 2025. Team of 12 including 3 PhDs and regulatory consultant.",
    "valuation": "",
    "use_of_funds": "Funding: Raising $15M Series A. Use of funds: 60% clinical trial execution, 25% manufacturing scale-up, 15% team expansion. Timeline: IND filing Q2 2025, Phase 1 start Q4 2025. Team of 12 including 3 PhDs and regulatory consultant.",
    "investors": [
      "Traction: Completed successful IND-enabling studies. Partnership discussions with Roche and Novartis. Received $2.5M NIH SBIR grant. 3 patients enrolled in compassionate use program showing 40% improvement in muscle function.",
      "Funding: Raising $15M Series A. Use of funds: 60% clinical trial execution, 25% manufacturing scale-up, 15% team expansion. Timeline: IND filing Q2 2025, Phase 1 start Q4 2025. Team of 12 including 3 PhDs and regulatory consultant."
    ],
    "milestones": ""
  },
  "analysis_metadata": {
    "model": "gpt-4",
    "timestamp": 1752894098.291425,
    "token_usage": 1889
  }
}